Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo.
about
Role of docosahexaenoic acid in the modulation of glial cells in Alzheimer's diseaseAPOE-modulated Aβ-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspectiveEffect of LXR/RXR agonism on brain and CSF Aβ40 levels in ratsAPOE4 enhances age-dependent decline in cognitive function by down-regulating an NMDA receptor pathway in EFAD-Tg mice.RNA-sequencing reveals transcriptional up-regulation of Trem2 in response to bexarotene treatment.Analysis of differential secondary effects of novel rexinoids: select rexinoid X receptor ligands demonstrate differentiated side effect profiles.Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABAA potentiating activity for use in dementia.Differential interaction of Apolipoprotein-E isoforms with insulin receptors modulates brain insulin signaling in mutant human amyloid precursor protein transgenic miceDifferential Effects of apoE4 and Activation of ABCA1 on Brain and Plasma Lipoproteins.Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease.Rescuing effects of RXR agonist bexarotene on aging-related synapse loss depend on neuronal LRP1A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease.Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots.Neuronally-directed effects of RXR activation in a mouse model of Alzheimer's disease.The emerging role of bexarotene in the treatment of Alzheimer's disease: current evidence.Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical EvidenceEFAD transgenic mice as a human APOE relevant preclinical model of Alzheimer's disease.Clinical drug research in chronic central neurodegenerative disorders.Do Cancer Drugs Counteract Neurodegeneration? Repurposing for Alzheimer's Disease.Therapeutic potential of nuclear receptor agonists in Alzheimer's disease.Apolipoprotein E, Receptors, and Modulation of Alzheimer's Disease.The Effect of the APOE4 Gene on Accumulation of Aβ40 After Brain Injury Cannot Be Reversed by Increasing apoE4 Protein.ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice.A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjectsAlzheimer's Disease: The Role of Microglia in Brain Homeostasis and Proteopathy.The Continuing Failure of Bexarotene in Alzheimer's Disease Mice.Apolipoprotein E Isoforms Differentially Regulate Alzheimer's Disease and Amyloid-β-Induced Inflammatory Response in vivo and in vitro.Nuclear receptor agonist-driven modification of inflammation and amyloid pathology enhances and sustains cognitive improvements in a mouse model of Alzheimer's disease.Inflammation: Bridging Age, Menopause and APOEε4 Genotype to Alzheimer's Disease
P2860
Q26766462-81129DB2-447D-4476-961F-96CDC58AEAAFQ28085213-6A5E2FA7-FD92-495D-991C-818274E7241FQ28602802-23658296-27B9-4CAB-82E0-BBFB6C2F32A6Q35337169-1C776052-FA4C-4826-8018-845994193328Q35662879-4B23D564-D489-47F4-AE8C-B8280B527B69Q35664947-00C5B8BA-86CC-4F04-B56D-55999817C566Q35813037-69F784C1-1B6F-48F9-9B08-311B0EA20978Q36034035-82B6E618-9BDB-4E19-B091-25FD74C31688Q36185793-0D69519A-266D-4227-9B2B-88844646329CQ36517542-A51FE03D-4858-43E5-9AEC-F1EB5BC9A1F1Q36600444-E99A929D-3450-4626-9CD7-59AA10D81F5EQ36850925-82CE3868-36D7-46BB-B307-D3ABF229BB9AQ36913723-8D99AC65-2DD5-4539-AB09-012293CB4019Q37644290-73EEBE4C-33FE-40AA-8070-037ADFF26D50Q38364682-8CBBFD11-4D56-412F-9340-F2EEA5CA87A3Q38407177-BC07B1D9-CB72-44A4-8BE7-FC91F209732BQ38733357-3D134FF0-CC58-47BE-8483-2515FE359BC0Q38763831-0A3C97B8-2C11-423A-AABE-AA5D4CF1E80BQ39005365-FB5E3E0E-A6A7-46A7-80CE-81C30845A719Q39164346-22CB2EA0-F3F5-4760-A2B2-5637A84D7A2FQ39257249-BFAE0B36-3DD2-450C-8030-60BC6890DAF7Q39686047-E8463712-6CF6-4155-96EF-6ED5F516E40EQ40736250-37ED18EB-A0CD-4F90-B525-149288624EA3Q42689665-93885B84-862C-4CE8-9973-C6D44B9AFAEEQ47222390-DF079821-FBE8-4557-B461-8BBE00DBC273Q47570646-5345CF33-DF80-41AA-833C-32E614D049FFQ48232697-1B45DEA8-6AB7-453B-9EBD-13317672F292Q49962878-D0A8F803-33BE-4AEF-9BAB-D66A714BDF39Q57816569-287E83F1-C573-4AEA-9DE9-79B18BFC602F
P2860
Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Amyloid-β pathology and APOE g ...... ptor agonist activity in vivo.
@ast
Amyloid-β pathology and APOE g ...... ptor agonist activity in vivo.
@en
Amyloid-β pathology and APOE g ...... ptor agonist activity in vivo.
@nl
type
label
Amyloid-β pathology and APOE g ...... ptor agonist activity in vivo.
@ast
Amyloid-β pathology and APOE g ...... ptor agonist activity in vivo.
@en
Amyloid-β pathology and APOE g ...... ptor agonist activity in vivo.
@nl
prefLabel
Amyloid-β pathology and APOE g ...... ptor agonist activity in vivo.
@ast
Amyloid-β pathology and APOE g ...... ptor agonist activity in vivo.
@en
Amyloid-β pathology and APOE g ...... ptor agonist activity in vivo.
@nl
P2093
P2860
P356
P1476
Amyloid-β pathology and APOE g ...... eptor agonist activity in vivo
@en
P2093
Gregory R J Thatcher
Kevin P Koster
Leon M Tai
Manel Ben Aissa
Nicole C Collins
Yue-ting Wang
P2860
P304
30538-30555
P356
10.1074/JBC.M114.600833
P407
P577
2014-09-12T00:00:00Z